PedAM
Pediatric Disease Annotations & Medicines
| Disease | thalassemia |
| Phenotype | C0029456|osteoporosis |
| Sentences | 11 |
| PubMedID- 23652868 | In a previous study aimed at comparing dxa and quantitative computed tomography (qct), mylona and colleagues observed a strong difference in the prevalence of osteopenia and osteoporosis in patients with β-thalassemia according to the technique used. |
| PubMedID- 22778734 | He prevalence of osteoporosis is high in patients with thalassemia major, possibly related to delayed puberty. |
| PubMedID- 25216685 | Considering the emerging importance of the endocannabinoid/endovanilloid system in bone metabolism, it may be instructive to examine a potential role for this system in the development of osteoporosis in patients with beta-thalassemia major and its relationship with iron overload and iron chelation therapy. |
| PubMedID- 20976089 | The pathogenesis of osteoporosis in thalassaemia major (tm) is complicated and differs from the pathogenesis of bone deformities characteristically found in nontransfused patients who develop bone distortion mainly due to ineffective haemopoiesis and progressive marrow expansion [3]. |
| PubMedID- 22581647 | We conclude that circulating sclerostin is elevated in thalassemia patients with osteoporosis and correlated with their bmd, but it was not reduced post zoledronic acid administration. |
| PubMedID- 26199898 | The most importantfactors for osteoporosis in thalassemia includedelayed puberty, diabetes mellitus, hypothyroidism,ineffective hematopoiesis with bone marrow hyperplasia,parathyroid gland dysfunction, toxic effectof iron on osteoblasts and deficiency of growthhormone/insulin-like growth factor-1 (gh/igf-1).in general, decreased bone density and osteoporosisare the result of a disrupted balance between osteoblastsand osteoclasts (5, 6). |
| PubMedID- 20694183 | In a study by otrock et al,60 18 thalassemia patients with osteoporosis were given zol 4 mg iv every 3 months over a period of 12 months. |
| PubMedID- 25002928 | Uncontrolled erythropoiesis and progressive marrow expansion are other causes of osteoporosis in thalassemia major and intermedia patients.osteoporosis is a side effect of iron toxicity on osteoblasts and also deferoxamine, an iron chelator which is used in these patients. |
| PubMedID- 24575552 | osteoporosis in thalassemia major: an update and the i-cet 2013 recommendations for surveillance and treatment. |
| PubMedID- 22966867 | Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in beta-thalassaemia presenting with osteopenia-osteoporosis syndrome. |
| PubMedID- 25849944 | The reported frequency of osteoporosis, in thalassemia mayor patients, despite adequate transfusion and iron chelation therapy, varies from 13.6% to 50% with an additional 45% affected by osteopenia [67]. |
Page: 1